812 related articles for article (PubMed ID: 16818948)
21. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
22. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
[TBL] [Abstract][Full Text] [Related]
23. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
Ma CY; Lu YC; Shi JX; Ren CC; Zhu JD; Gu JR
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(4):262-6. PubMed ID: 15854489
[TBL] [Abstract][Full Text] [Related]
24. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects.
Ray P; Tsien R; Gambhir SS
Cancer Res; 2007 Apr; 67(7):3085-93. PubMed ID: 17409415
[TBL] [Abstract][Full Text] [Related]
25. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo.
Dilber MS; Abedi MR; Christensson B; Björkstrand B; Kidder GM; Naus CC; Gahrton G; Smith CI
Cancer Res; 1997 Apr; 57(8):1523-8. PubMed ID: 9108455
[TBL] [Abstract][Full Text] [Related]
26. [In vitro killing effect of mutant thymidine kinase mediated by lentiviral vector on T lymphocytes].
Xu KL; Pan XY; Yang YJ; Lu QX; Li ZY; He XP
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):678-81. PubMed ID: 16620557
[TBL] [Abstract][Full Text] [Related]
27. [Studies on herpes simplex virus thymidine kinase gene and GCV system for treatment of human bladder carcinoma].
He J; Chen Y; Li H; Lu Y; Yan Y; Tan X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Jun; 21(3):428-32. PubMed ID: 15250149
[TBL] [Abstract][Full Text] [Related]
28. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V).
Pavlovic J; Nawrath M; Tu R; Heinicke T; Moelling K
Gene Ther; 1996 Jul; 3(7):635-43. PubMed ID: 8818652
[TBL] [Abstract][Full Text] [Related]
30. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography.
Yaghoubi SS; Barrio JR; Namavari M; Satyamurthy N; Phelps ME; Herschman HR; Gambhir SS
Cancer Gene Ther; 2005 Mar; 12(3):329-39. PubMed ID: 15592447
[TBL] [Abstract][Full Text] [Related]
31. Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector.
Iijima Y; Ohno K; Ikeda H; Sawai K; Levin B; Meruelo D
Int J Cancer; 1999 Jan; 80(1):110-8. PubMed ID: 9935240
[TBL] [Abstract][Full Text] [Related]
32. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
Kong BH; Wang WX; Liu CS; Ma DX; Qu X
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
[TBL] [Abstract][Full Text] [Related]
33. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
34. An experimental application of gene therapy for human retinoblastoma.
Hayashi N; Ido E; Ohtsuki Y; Ueno H
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):265-72. PubMed ID: 9950583
[TBL] [Abstract][Full Text] [Related]
35. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene.
Carrió M; Romagosa A; Mercadé E; Mazo A; Nadal M; Gómez-Foix AM; Fillat C
Gene Ther; 1999 Apr; 6(4):547-53. PubMed ID: 10476214
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach.
Brand K; Löser P; Arnold W; Bartels T; Strauss M
Gene Ther; 1998 Oct; 5(10):1363-71. PubMed ID: 9930342
[TBL] [Abstract][Full Text] [Related]
37. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].
Wang YP; Tang XJ; Zhou QH; Che GW; Chen XH; Zhu DX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):701-5. PubMed ID: 19024294
[TBL] [Abstract][Full Text] [Related]
38. 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET.
Iyer M; Barrio JR; Namavari M; Bauer E; Satyamurthy N; Nguyen K; Toyokuni T; Phelps ME; Herschman HR; Gambhir SS
J Nucl Med; 2001 Jan; 42(1):96-105. PubMed ID: 11197989
[TBL] [Abstract][Full Text] [Related]
39. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
40. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
